PI

Forxiga is the first and only approved SGLT2i for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction1

See how you can help your Type 2 Diabetes
patients with or at risk of heart failure

See how you can help
your HF patients

Prescribing Information

See how you can help your Type 2 Diabetes
patients with or at risk of heart failure

See how you can help
your HF patients

Forxiga is the first and only approved SGLT2i for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction1

Cardiovascular, renal and metabolic diseases are some of the leading causes of death around the world.2,3 At AstraZeneca, our vision is to protect the lives of the millions of people in the UK affected by these conditions.4-6

Book an appointment

tick-icon

New NICE recommendation

FORXIGA 10mg: Recommended as a treatment option for symptomatic chronic heart failure with reduced ejection fraction, only if added to optimised standard care (on advice of a specialist)7

 

See the DAPA-HF data that led to NICE recommendation >

HFrEF, heart failure with reduced ejection fraction; NICE, National Institute for Health and Care Excellence

 

References:

1. FORXIGA (dapagliflozin) 10 mg film‑coated tablets Summary of Product Characteristics. November 2020

2. World Health Organisation. The top ten causes of death. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Last accessed: October 2020.

3. Luyckx VA et al. The global burden of kidney disease and the sustainable development goals. Available at: https://www.who.int/bulletin/volumes/96/6/17-206441/en/#:~:text=In%202010%2C%20an%20estimated%202.3,without%20access%20to%20chronic%20dialysis.&text=Additionally%2C%20each%20year%2C%20around%201.7,die%20from%20acute%20kidney%20injury.&text=Overall%2C%20therefore%2C%20an%20estimated%20 5,die%20annually%20from%20kidney%20disease. Last accessed October 2020.

4. British Heart Foundation. Facts and figures. Available at: https://www.bhf.org.uk/what-we-do/news-from-the-bhf/contact-the-press-office/facts-and-figures#:~:text=There%20are%20around%207.4%20million,the%20single%20biggest%20killer%20worldwide. Accessed October 2020.

5. Diabetes UK. Diabetes prevalence 2019. Available at: https://www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2019. Accessed October 2020.

6. Kidney Care UK. Facts and stats. Available at: https://www.kidneycareuk.org/news-and-campaigns/facts-and-stats/. Accessed October 2020.

7. NICE Technology Appraisal Guidance: Dapagliflozin for treating heart failure with reduced ejection fraction [TA679]. February 2021. Available at: https://www.nice.org.uk/guidance/ta679

Back to top